How the Pulmonary Or Respiratory Drug Delivery Market Will Grow: Key Trends, Market Size, and Opportunities Beyond 2025
2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!
What Industry-Specific Factors Are Fueling the Growth of thePulmonary Or Respiratory Drug Delivery Market?
The pulmonary or respiratory drug delivery market is being propelled by the rising incidences of pneumonia. This lung infection causes inflammation of air sacs, which may become filled with fluid or pus, resulting in symptoms such as cough, fever, and difficulty in breathing. Factors such as aging populations, compromised immune systems, respiratory infections, air pollution, smoking, and the emergence of antibiotic-resistant bacteria contribute to the increasing cases of pneumonia. Pulmonary or respiratory drug delivery aids patients with pneumonia by specifically targeting the lungs with treatments like antibiotics, bronchodilators, or anti-inflammatory agents, in turn, offering quicker and more efficient relief from symptoms, reducing inflammation, eliminating infections, and improving respiratory function. This ultimately leads to improved recovery rates and reduced complications. The Centre for Tropical Medicine and Global Health, a UK-based healthcare research leader, reported in November 2023 that the number of pneumonia cases in Kenya climbed significantly, hitting 793,864 cases in 2022/2023. As a result, the rising occurrence of pneumonia fuels the growth of the pulmonary or respiratory drug delivery market.
Get Your Free Sample Report Now – Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20939&type=smp
#What Long-Term Growth Rate is Expected for thePulmonary Or Respiratory Drug Delivery Market Between 2025 and 2034?
The market size for pulmonary or respiratory drug delivery has seen considerable growth in the recent past. The market, which was worth $69.83 billion in 2024, is projected to rise to $76.38 billion in 2025, reflecting a compound annual growth rate (CAGR) of 9.4%. Factors contributing to this growth during the historical period include a rise in the prevalence of asthma, increased uptake of innovative inhalation devices, a global increase in healthcare spending, enhanced awareness of respiratory diseases, and an uptick in the occurrence of allergic conditions.
The market size of pulmonary or respiratory drug delivery is predicted to experience significant growth in the forthcoming years, rising to $107.85 billion in 2029 with a compound annual growth rate (CAGR) of 9.0%. The projected growth during this period is due to factors such as the increasing demand for personalized medicine, the expanding incidence of chronic respiratory illnesses, the emphasis on telemedicine, increasing investment in the healthcare infrastructure, and the growth of e-commerce in the pharmaceutical sector. Key trends expected during this period include the improvement in particle engineering, the production of advanced nebulizers, the creation of liposomal formulations, advances in computational fluid dynamics, and the development of smart inhalers.
You can Directly Purchase the Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20939
What Key Market Trends and Innovations Are Shaping the Future of thePulmonary Or Respiratory Drug Delivery Industry?
In the pulmonary or respiratory drug delivery market, prominent companies are highlighting innovations like advanced drug delivery systems to improve the effectiveness of treatments and patient adherence. Advanced drug delivery systems are state-of-the-art solutions designed to enhance the precise delivery and controlled release of medical treatments, which in turn boosts their effectiveness and patient results. Take for example, in July 2023, Viatris Inc., an American healthcare business that produces generic and branded medications, partnered with Kindeva Drug Delivery L.P., a US firm specializing in drug delivery, to introduce Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol. This inhalation aerosol was sanctioned by the Food and Drug Administration, a U.S. government institution. Marking the first generic model of AstraZeneca’s Symbicort, this metered-dose inhaler amalgamates budesonide and formoterol for the management of asthma and chronic obstructive pulmonary disease. It can be found in two potencies, specifically 80 micrograms and 160 micrograms, along with 4.5 micrograms of formoterol.
Which Companies Are Leading the Charge in Expanding thePulmonary Or Respiratory Drug Delivery Market Growth?
Major companies operating in the pulmonary or respiratory drug delivery market are Merck & Co. Inc., Novartis AG, Thermo Fisher Scientific Inc., AstraZeneca plc, Abbott Laboratories, 3M Company, Koninklijke Philips N.V., GlaxoSmithKline, Omron Corporation, Teva Pharmaceutical Industries Ltd., Aptar Pharma, Sumitomo Pharma America Inc., Chiesi Farmaceutici S.p.A., Cipla Inc., Boehringer Ingelheim GmbH, Kindeva Drug Delivery Limited, Nemera Group, Hovione, H And T Presspart Group, Vectura Group plc
Order Your Report Now For A Swift Delivery:
How is the Global Pulmonary Or Respiratory Drug Delivery Market Segemented?
The pulmonary or respiratory drug delivery market covered in this report is segmented –
1) By Product: Formulation Type, Device Type
2) By Canister Type: Plain Canister, Coated Canister
3) By Application: Chronic Obstructive Pulmonary Disease, Asthma, Cystic Fibrosis, Other Applications
4) By End-User: Hospitals, Clinics, Home Care Settings
Subsegments:
1) By Formulation Type: Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), Nebulizers, Liquid Aerosols, Nasal Sprays
2) By Device Type: Inhalers (Manual and Digital), Nebulizers (Compressor, Ultrasonic, Mesh), Breath-Activated Devices, Spacer Devices, Nasal Drug Delivery Devices
Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=20939&type=smp
Which Geographics are Influencing the Growth of the Pulmonary Or Respiratory Drug Delivery Market?
North America was the largest region in the pulmonary or respiratory drug delivery market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pulmonary or respiratory drug delivery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Reports Similar to the Global Pulmonary Or Respiratory Drug Delivery Market 2025, By The Business Research Company:
Pulmonary Arterial Hypertension Global Market Report 2025
https://thebusinessresearchcompany.com/report/pulmonary-arterial-hypertension-global-market-report
Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Global Market Report 2025
Idiopathic Pulmonary Fibrosis Global Global Market Report 2025
https://thebusinessresearchcompany.com/report/idiopathic-pulmonary-fibrosis-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.
